IL-23 drives uveitis by acting on a population of tissue-resident entheseal T cells
Hedley R. et al, (2025), Jci insight
The complex relationship between clinical disease activity, synovial inflammatory profile and treatment response in RA
Triaille C. et al, (2025), The lancet rheumatology
STAT3 phosphorylation in the rheumatoid arthritis immunological synapse.
Novak-Kotzer H. et al, (2025), J autoimmun, 155
Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study
Gossec L. et al, (2025), Arthritis research & therapy
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
Ebbers H. et al, (2025), Rheumatology and therapy
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Taylor PC. et al, (2025), Annals of the rheumatic diseases
Cosmological gravity on all scales. Part IV. 3× 2 pt Fisher forecasts for pixelised phenomenological modified gravity
Srinivasan S. et al, (2025), Journal of cosmology and astroparticle physics, 2025, 071 - 071
Association between patient-reported pain and remission or low disease activity in patients with rheumatoid arthritis: Data from RA-BE-REAL prospective observational study
Taylor PC. et al, (2024), Rheumatology and therapy
Design and Rationale of MYOFLAME-19 RCT: MYOcardial protection to reduce inFLAMmatory heart disease due to COVID-19 Infection using CMR Endpoints.
Puntmann VO. et al, (2024), J cardiovasc magn reson
Does concomitant use of methotrexate with JAK inhibition confer benefit for cardiovascular outcomes? A commentary
Taylor PC. et al, (2024), Rheumatology and therapy
Inflammatory disease status and response to TNF blockade are associated with mechanisms of endotoxin tolerance.
Clanchy FI. et al, (2024), J autoimmun, 148
What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?
Taylor PC. et al, (2024), Therapeutic advances in musculoskeletal disease
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
Buch MH. et al, (2024), Rheumatology
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
Smolen JS. et al, (2024), Rheumatology
Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial
Uhrenholt L. et al, (2024), Rheumatology international